Evercore ISI keeps McKesson stock Outperform on Apollo stake deal By Investing.com

Evercore ISI reiterated an Outperform rating on McKesson and a $950 price target after Apollo agreed to buy a 13% stake in Medical-Surgical Solutions for $1.25 billion, implying a $13 billion valuation. The deal is viewed as positive because it validates the asset’s standalone value and helps de-risk the planned separation and IPO process. Analyst commentary also highlights McKesson’s attractive valuation metrics, including a PEG ratio of 0.41.

Analysis

This is less about the incremental economics of the stake sale and more about signaling: Apollo’s willingness to write a large check effectively compresses the uncertainty discount around the carve-out. The market should start treating the medical-surgical unit as a separately financeable asset with an observable clearing price, which improves the odds of a cleaner IPO narrative and narrows the range of outcomes on the parent’s sum-of-the-parts valuation.

Second-order, the transaction creates a strategic moat for McKesson’s separation process because it imports a capital-markets sponsor with incentive to validate valuation and structure, not just provide capital. That matters because the value creation here is likely to come from multiple expansion over the next 6-12 months, not from near-term earnings beats; in other words, the catalyst is financial engineering plus disclosure, not operating acceleration. The real risk is that investors misread this as a growth fix when it is primarily a de-risking step for a slower re-rating process.

The contrarian concern is that the valuation implied by the deal may be a ceiling as much as a floor. If the broader healthcare distribution complex de-rates or if the prescription technology segment slows, the market may stop paying for optionality and instead focus on core growth quality, which could cap upside even with a successful separation. So the trade works best if you believe the next 2-3 quarters will feature continued proof points on capital allocation and asset monetization rather than a broad healthcare multiple reset.

Key Decisions for Investors

• Stay long MCK into the next 3-6 months for a valuation re-rating trade; target a move toward the street’s higher end if the market starts assigning a cleaner SOTP discount, with downside limited by the external validation of the unit.
• Use call spreads on MCK rather than outright stock if entering after the announcement; the setup is more about multiple expansion than earnings acceleration, so defined-risk upside is better than paying full delta.
• Pair MCK long against a slower-growth healthcare distributor or broad managed-care basket over the next quarter to isolate the benefit of asset monetization and separation optionality from sector beta.